Tsuji M, Murakami Y, Kanayama H, Sano T, Kagawa S
Department of Urology, School of Medicine, University of Tokushima, Japan.
Br J Urol. 1998 Jan;81(1):116-21. doi: 10.1046/j.1464-410x.1998.00492.x.
To determine differences in the immunohistochemical (IHC) expression of Bcl-2 protein and Ki-67 antigen in patients with prostatic cancer who underwent radical prostatectomy with or without neoadjuvant hormonal therapy.
Ki-67 antigen and Bcl-2 protein were detected by IHC using MIB-1 and Bcl-2 antibodies in prostatectomy specimens from 28 patients who received hormonal therapy before surgery (group 1) and 51 patients who did not (group 2).
In group 2, the mean MIB-1 index increased with increasing grade of tumour, from 11.6% in low-grade to 24.7% in high-grade tumours (P = 0.002). Bcl-2 expression did not correlate with either tumour grade or stage. In group 1, there were no correlations between Bcl-2 expression or MIB-1 index and tumour grade or stage. More tumours in group 1 were Bcl-2-positive (16 of 28, 57%) than were tumours in group 2 (11 of 51, 22%; P = 0.003). The mean (SD) MIB-1 index of tumours in group 2 [15.6 (14.4)%], was significantly greater than that of tumours in group 2 [6.8 (7.5)%; P = 0.004].
These results indicate that Bcl-2 positivity is increased by androgen ablation therapy and conversely, that the proliferative activity of cancer cells is significantly reduced. The expression of Bcl-2 protein may play a role in the ability of prostate cancer cells to survive in an androgen-deprived environment.
确定接受或未接受新辅助激素治疗的前列腺癌患者在接受根治性前列腺切除术后，其Bcl-2蛋白和Ki-67抗原的免疫组化（IHC）表达差异。
使用MIB-1和Bcl-2抗体，通过免疫组化法检测28例术前接受激素治疗患者（第1组）和51例未接受激素治疗患者（第2组）前列腺切除标本中的Ki-67抗原和Bcl-2蛋白。
在第2组中，平均MIB-1指数随肿瘤分级增加而升高，从低级别肿瘤的11.6%升至高级别肿瘤的24.7%（P = 0.002）。Bcl-2表达与肿瘤分级或分期均无相关性。在第1组中，Bcl-2表达或MIB-1指数与肿瘤分级或分期之间无相关性。第1组中Bcl-2阳性的肿瘤（28例中的16例，57%）比第2组中的肿瘤（51例中的11例，22%；P = 0.003）更多。第2组肿瘤的平均（标准差）MIB-1指数[15.6（14.4）%]显著高于第1组肿瘤的平均（标准差）MIB-1指数[6.8（7.5）%；P = 0.004]。
这些结果表明，雄激素剥夺治疗可增加Bcl-2阳性率，相反，癌细胞的增殖活性显著降低。Bcl-2蛋白的表达可能在前列腺癌细胞在雄激素缺乏环境中存活的能力中起作用。
